Isomorphic Labs published a technical report describing IsoDDE, a proprietary drug‑discovery engine the company says advances protein–drug and antibody interaction predictions. Scientists quoted in Nature called the model a major step — likening its impact to a hypothetical “AlphaFold 4” — but raised concerns because Isomorphic is not releasing full methodological details. The announcements come nearly two years after DeepMind’s AlphaFold3 work and highlight tension between closed commercial systems and the open‑source community trying to reproduce cutting‑edge capabilities. Isomorphic presented case studies of precise protein interaction and antibody structure predictions in its 27‑page report. Companies and academic groups that rely on open tools for reproducibility are now re‑evaluating collaboration and IP strategies; proprietary leaps could accelerate drug discovery but also concentrate advantage with firms that control the models.